-
Amgen's Kyprolis Fails To Met Endpoint, But It's Not All Bad News
Wednesday, September 28, 2016 - 10:02am | 364Amgen, Inc. (NASDAQ: AMGN) announced that the Phase 3 CLARION trial for Kyprolis in first-line multiple myeloma (MM) did not meet the primary endpoint. Goldman Sachs’ Terence Flynn maintains a Buy rating on the company, while lowering the price target from $206 to $198. Disappointing Data...